Global first for Salford team in rare disease study

Congratulations to the Salford Royal Core Research Team, Professor Hector Chinoy (PI) and Dr James Lilleker for dosing the first patient globally in a study testing the efficacy and safety of a new treatment for a rare inflammatory muscle disease.

Immune-mediated necrotizing myopathy, a type of myositis where muscle damage causes weakness and fatigue, doesn’t yet have a cure, although there are treatments to help manage its debilitating symptoms.

The new Phase 2 study, sponsored by Ra Pharmaceuticals, Inc., is testing an investigational drug, zilucoplan, which is designed to prevent the body’s immune attack on muscle cells by blocking a component of the body’s immune system called the complement pathway.

It aims to recruit 24 patients worldwide, and the first was dosed at Salford Royal’s Clinical Research Facility on 3 December.

She is pictured (front) with Dr Lilleker (sub-investigator and clinical evaluator) and the research nursing team.

You can read more here on Ra Pharmaceuticals, Inc’s website